Program
FGFR3/4 Inhibitor TYRA-430
Its studies are mostly in Carcinoma, Hepatocellular, led by Tyra Biosciences.
Furthest: phase 1, since Mar 31, 20251 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tyra Biosciences | 11 open or running | phase 1since Mar 31, 2025 | Mar 31, 2025 | Jan 2028phase 1 · NCT06915753 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 31, 2025First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT06915753 · 125 planned · United States, Canada, South Korea and more
Ahead
- Jan 2028Primary completion: phase 1 study in Carcinoma, HepatocellularNCT06915753
TargetBeta
FGFR3 →read by rule
“An orally bioavailable reversible inhibitor of fibroblast growth factor receptor (FGFR) types 3 and 4 (FGFR3/4), ”NCIt, by rule
Other programs on FGFR3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| masitinibrule | AB Science | phase 3 | 38 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| pemigatinibrule | Incyte | phase 3 | 16 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| vepugratinibrule | Eli Lilly | phase 3 | 5 |
| dabogratinibrule | Tyra Biosciences | phase 2 | 5 |
| Anti-FGFR3 Antibody-drug Conjugate BHV-1530rule | biohaven-therapeutics-ltd | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06915753Carcinoma, Hepatocellular · United States, Canada, South Korea and more | 1 | Recruiting | Jan 2028 | 125 |
How it is read
Names in the registry
- “TYRA-430”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.